IL293091A - Methods for administering continuous anti-pnag therapy involving bacteria - Google Patents

Methods for administering continuous anti-pnag therapy involving bacteria

Info

Publication number
IL293091A
IL293091A IL293091A IL29309122A IL293091A IL 293091 A IL293091 A IL 293091A IL 293091 A IL293091 A IL 293091A IL 29309122 A IL29309122 A IL 29309122A IL 293091 A IL293091 A IL 293091A
Authority
IL
Israel
Prior art keywords
charged
reactor
column
bowl
vaccine
Prior art date
Application number
IL293091A
Other languages
English (en)
Hebrew (he)
Original Assignee
Alopexx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alopexx Inc filed Critical Alopexx Inc
Publication of IL293091A publication Critical patent/IL293091A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL293091A 2019-11-22 2020-11-20 Methods for administering continuous anti-pnag therapy involving bacteria IL293091A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962939331P 2019-11-22 2019-11-22
US202062994130P 2020-03-24 2020-03-24
PCT/US2020/061594 WO2021102320A1 (en) 2019-11-22 2020-11-20 Methods for providing continuous therapy against pnag comprising microbes

Publications (1)

Publication Number Publication Date
IL293091A true IL293091A (en) 2022-07-01

Family

ID=75980043

Family Applications (1)

Application Number Title Priority Date Filing Date
IL293091A IL293091A (en) 2019-11-22 2020-11-20 Methods for administering continuous anti-pnag therapy involving bacteria

Country Status (11)

Country Link
US (1) US20230053458A1 (OSRAM)
EP (1) EP4061411A4 (OSRAM)
JP (2) JP2023502276A (OSRAM)
KR (1) KR20220107001A (OSRAM)
CN (1) CN114845731A (OSRAM)
AU (1) AU2020386971A1 (OSRAM)
BR (1) BR112022009924A2 (OSRAM)
CA (1) CA3162238A1 (OSRAM)
IL (1) IL293091A (OSRAM)
WO (1) WO2021102320A1 (OSRAM)
ZA (1) ZA202205546B (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220079534A (ko) * 2019-08-27 2022-06-13 알로펙스, 인크. 항미생물 백신 조성물
US11173199B2 (en) * 2019-11-13 2021-11-16 Alopexx Inc. Low contaminant compositions
US20260015434A1 (en) * 2022-03-11 2026-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Antibody materials and methods targeting microbial polysaccharides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103084A2 (en) * 2004-04-21 2005-11-03 The Brigham And Women's Hospital, Inc. Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof
NZ591103A (en) * 2008-07-21 2013-02-22 Brigham & Womens Hospital Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
US20130116423A1 (en) * 2010-04-23 2013-05-09 A. Stewart Campbell Synthetic Oligosaccharides for Staphylococcus Vaccine
WO2012145626A1 (en) * 2011-04-22 2012-10-26 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphylococcus vaccine
EP2847216A1 (en) * 2012-05-07 2015-03-18 Sanofi Methods for preventing biofilm formation
JP2015517496A (ja) * 2012-05-07 2015-06-22 サノフイ バイオフィルム形成を防止する方法
RU2019101166A (ru) * 2012-05-30 2020-03-02 Дзе Брихэм Энд Уимен`З Хоспитал, Инк. Композиции полисахаридов и способы применения
US10828360B1 (en) * 2020-02-04 2020-11-10 OneBioPharma, Inc. Methods for inhibiting biofilm formation

Also Published As

Publication number Publication date
WO2021102320A1 (en) 2021-05-27
US20230053458A1 (en) 2023-02-23
JP2026016535A (ja) 2026-02-03
EP4061411A1 (en) 2022-09-28
EP4061411A4 (en) 2023-11-29
KR20220107001A (ko) 2022-08-01
BR112022009924A2 (pt) 2022-08-09
CN114845731A (zh) 2022-08-02
JP2023502276A (ja) 2023-01-23
ZA202205546B (en) 2023-05-31
AU2020386971A1 (en) 2022-06-09
CA3162238A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
CN111448205B (zh) 抗肺炎克雷伯菌的疫苗
CN102159540B (zh) 与合成的β-1,6葡糖胺寡糖相关的方法和组合物
JP2026016535A (ja) Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法
HK1252262A1 (zh) 结合抗糖鞘脂糖蛋白表位抗体的碳水化合物配体
JP2024524613A (ja) Ｍ６ｐｒ細胞表面受容体結合化合物及びコンジュゲート
IL297377A (en) Drug administration system for local administration of therapeutic substances and its uses
US20210244808A1 (en) Methods for inhibiting biofilm formation
JP2026021461A (ja) 低汚染抗菌ワクチン
US20250340580A1 (en) Tetrasaccharides for the diagnosis, prevention, and treatment of melioidosis and glanders
KR102803369B1 (ko) 클로스트리듐 디피실에 대한 안정성 백신
US10376593B2 (en) Glycoconjugates and their use as potential vaccines against infection by Shigella flexneri
EP4021491A1 (en) Antimicrobial vaccine compositions
HK40077830A (en) Methods for providing continuous therapy against pnag comprising microbes
CA3212271A1 (en) Pathogen moieties and uses thereof
IL322871A (en) Compositions and methods for targeting tumor-associated macrophages